Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Non-Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $4.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 1.6% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Sep 2025, down 1.6%, and an annual FY2024 reading of $4.7 million, down 20.98% over the prior year.
  • Total Non-Current Liabilities was $4.9 million for Q3 2025 at Kiora Pharmaceuticals, down from $6.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $6.6 million in Q2 2025 and bottomed at $3.8 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $5.2 million, with a median of $5.0 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 213.68% in 2021, then tumbled 40.75% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $3.9 million in 2021, then rose by 5.2% to $4.1 million in 2022, then soared by 43.93% to $6.0 million in 2023, then dropped by 20.98% to $4.7 million in 2024, then rose by 3.32% to $4.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KPRX at $4.9 million in Q3 2025, $6.6 million in Q2 2025, and $5.0 million in Q1 2025.